List of Excipients in API gilteritinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing gilteritinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | XOSPATA | gilteritinib | 0469-1425 | FERRIC OXIDE RED | 2036-07-01 |
| Astellas Pharma US Inc | XOSPATA | gilteritinib | 0469-1425 | HYDROXYPROPYL CELLULOSE | 2036-07-01 |
| Astellas Pharma US Inc | XOSPATA | gilteritinib | 0469-1425 | HYPROMELLOSE | 2036-07-01 |
| Astellas Pharma US Inc | XOSPATA | gilteritinib | 0469-1425 | LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE | 2036-07-01 |
| Astellas Pharma US Inc | XOSPATA | gilteritinib | 0469-1425 | MAGNESIUM STEARATE | 2036-07-01 |
| Astellas Pharma US Inc | XOSPATA | gilteritinib | 0469-1425 | MANNITOL | 2036-07-01 |
| Astellas Pharma US Inc | XOSPATA | gilteritinib | 0469-1425 | POLYETHYLENE GLYCOL | 2036-07-01 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for gilteritinib
Excipient focus: FERRIC OXIDE RED
gilteritinib drug variants containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| Astellas Pharma US Inc | gilteritinib | 0469-1425 |
| >Company | >Ingredient | >NDC |
gilteritinib drug variants not containing FERRIC OXIDE RED
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYDROXYPROPYL CELLULOSE
gilteritinib drug variants containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Astellas Pharma US Inc | gilteritinib | 0469-1425 |
| >Company | >Ingredient | >NDC |
gilteritinib drug variants not containing HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE
gilteritinib drug variants containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| Astellas Pharma US Inc | gilteritinib | 0469-1425 |
| >Company | >Ingredient | >NDC |
gilteritinib drug variants not containing HYPROMELLOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
gilteritinib drug variants containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| Astellas Pharma US Inc | gilteritinib | 0469-1425 |
| >Company | >Ingredient | >NDC |
gilteritinib drug variants not containing LOW-SUBSTITUTED HYDROXYPROPYL CELLULOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
gilteritinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Astellas Pharma US Inc | gilteritinib | 0469-1425 |
| >Company | >Ingredient | >NDC |
gilteritinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
gilteritinib drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Astellas Pharma US Inc | gilteritinib | 0469-1425 |
| >Company | >Ingredient | >NDC |
gilteritinib drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
gilteritinib drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Astellas Pharma US Inc | gilteritinib | 0469-1425 |
| >Company | >Ingredient | >NDC |
gilteritinib drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
gilteritinib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Astellas Pharma US Inc | gilteritinib | 0469-1425 |
| >Company | >Ingredient | >NDC |
gilteritinib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
gilteritinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Astellas Pharma US Inc | gilteritinib | 0469-1425 |
| >Company | >Ingredient | >NDC |
gilteritinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch